Palmer, D. H.
Ma, Y. T.
Peck-Radosavljevic, M.
Ross, P.
Graham, J.
Fartoux, L.
Deptala, A.
Studeny, M.
Schnell, D.
Hocke, J.
Loembé, A-B.
Meyer, T.
Article History
Received: 27 July 2017
Revised: 31 January 2018
Accepted: 12 February 2018
First Online: 22 March 2018
Competing interests
: D.H.P reports travel expenses from Boehringer Ingelheim and grants from Bayer, outside the submitted work. A-B.L., J.H., M.S., and D.S. are employees of Boehringer Ingelheim. Y.T.M reports personal fees from Bayer during the conduct of the study. T.M. reports consulting and conference travel expenses. M.P-R reports per patient fees for a phase III trial from Boehringer Ingelheim during the conduct of the study; and grants and personal fees from Bayer Healthcare, Lilly, Arqle-Daiichi, and other from ONXEO, outside the submitted work. P.R., J.G., L.F. and A.D report no relevant conflicts of interest.